2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
tislelizumab, BGB-A317
Class :
Antineoplastic, Immune checkpoint inhibitor, PD-1/PD-L1 Inhibitors
Brand Name :
N/A
Synonyms :
tislelizumab, BGB-A317
Class :
Antineoplastic, Immune checkpoint inhibitor, PD-1/PD-L1 Inhibitors
FDA approval is pending for unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in persons who have previously had systemic therapy
N/A
N/A
Actions and Spectrum:
Actions:
Tislelizumab is a programmed death receptor-1 (PD-1) inhibitor that is used to treat some types of cancer. PD-1 is a protein found on the surface of T cells that helps to regulate the immune system. Some cancer cells can use the PD-1 pathway to avoid identification and attack by the immune system. PD-1 inhibitors, such as tislelizumab, function by inhibiting this mechanism, allowing the immune system to recognize and destroy cancer cells more effectively.
Spectrum:
Tislelizumab is a programmed death receptor-1 (PD-1) inhibitor, and its primary mode of action is in the immune system and its interaction with cancer cells. Tislelizumab’s primary goal is to boost the body’s immune response against cancer cells.
N/A
N/A
N/A
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Tislelizumab is a programmed cell death-1 (PD-1) immune checkpoint inhibitor that is humanized IgG4 monoclonal antibody. The PD-1 pathway is an immunological control checkpoint that tumor cells may use to avoid active T-cell surveillance. Tislelizumab binds with high specificity and affinity to the extracellular domain of PD-1 on activated T cells, effectively preventing the binding of both PD-L1 and PD-L2 ligands produced on tumor cells. Tislelizumab works to restore antitumor immunity and slow tumor growth by inhibiting PD-1 signaling.
Pharmacodynamics: N/A
Pharmacokinetics: N/A
N/A
Patient information leaflet
Generic Name: tislelizumab
Pronounced: tis-lel-i-zu-mab
Why do we use tislelizumab?
Tislelizumab is a programmed death receptor-1 (PD-1) inhibitor that is used to treat some types of cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
